OrthoBio Therapeutics, Inc.
Regenerative medicine therapies for orthopedic conditions using innovative biological approaches
Follows are private to you and power your alerts
Updated · orthobiotherapeutics.com
- Sector
- Biotech
- Headquarters
- Vail, CO
- Latest Form D
- $31.4M, Jul 2025
- Total capital
- $31.4M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $31.4M
- 1 Form D · last Jul 2025
- 16 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 4
- 36 pending · first 2021
- Rank in peer group#293 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$31.4M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#293 · top 20%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Jessica T. HopfieldDirectorNamed in SEC Form D filings
- Lodewijk J. de VinkDirectorNamed in SEC Form D filings
- Marc J. PrisantExecutive OfficerNamed in SEC Form D filings
- Peter J. MillettExecutive Officer, DirectorNamed in SEC Form D filings
- Robert T. HuginDirectorNamed in SEC Form D filings
- Stanley T. ShumanDirectorNamed in SEC Form D filings
Show all 7 people
- William T. EsreyDirectorNamed in SEC Form D filings
What it has protected
USPTO · 4 granted of 40- PendingGene Editing to Improve Joint FunctionUSPTOApplication 19318731
- PendingGene Editing For Intervertebral, Intra- And Peridiscal Therapy And Associated Spinal DisordersUSPTOApplication 18855980
- GrantedGene Editing to Improve Joint FunctionUSPTOUS 12,419,968
Show all 40 patent records
- Gene Editing to Improve Joint FunctionAug 27, 2026 · Application 19318731Pending
- Gene Editing For Intervertebral, Intra- And Peridiscal Therapy And Associated Spinal DisordersJul 16, 2026 · Application 18855980Pending
- Gene Editing to Improve Joint FunctionSep 23, 2025 · US 12,419,968Granted
- Lipid Nanoparticles For Gene Editing SystemsAug 21, 2025 · Application 18856005Pending
- Gene Editing To Improve Joint FunctionJul 17, 2025 · Application 18832443Pending
- Gene Editing To Improve Joint FunctionMay 22, 2025 · Application 18832462Pending
- Transmembrane Receptor Gene EditingMay 22, 2025 · Application 18729791Pending
- Gene Editing to Improve Joint FunctionMay 6, 2025 · US 12,290,572Granted
- Gene Editing To Improve Joint FunctionSep 12, 2024 · Application 18006455Pending
- Gene Editing To Improve Joint FunctionAug 17, 2023 · Application 18005544Pending
- Gene Editing To Improve Joint FunctionJul 27, 2023 · Application 17867486Pending
- Gene Editing to Improve Joint FunctionMay 10, 2022 · US 11,324,838Granted
- Gene Editing to Impove Joint FunctionJun 15, 2021 · US 11,033,590Granted
- Lipid Nanoparticles For Gene Editing SystemsApplication 63551019Pending
- Gene Editing For Intervertebral, Intra- And Peridiscal Therapy And Associated Spinal DisordersApplication 63551014Pending
- Gene Editing For Surgery-related Fibrosis TreatmentApplication PCTUS2024012268Pending
- Engineered Crispr Associated ProteinsApplication 63591438Pending
- Lipid Nanoparticlees For Gene Editing SystemsApplication 63591352Pending
- Lipid Nanoparticles For Gene Editing SystemsApplication 63515817Pending
- Transmembrane Receptor Gene EditingApplication 63515813Pending
- Gene Editing For Intervertebral, Intra- And Peridiscal Therapy And Associated Spinal DisordersApplication 63515811Pending
- Gene Editing For Intervertebral, Intra- And Peridiscal Therapy And Associated Spinal DisordersApplication 63495741Pending
- Lipid Nanoparticles For Gene Editing SystemsApplication PCTUS2023065691Pending
- Gene Editing For Intervertebral, Intra- And Peridiscal Therapy And Associated Spinal DisordersApplication PCTUS2023065684Pending
- Lipid Nanoparticles For Gene Editing SystemsApplication 63495461Pending
- Lipid Nanoparticles For Gene Editing SystemsApplication 63495474Pending
- Gene Editing To Improve Joint FunctionApplication PCTUS2023061407Pending
- Gene Editing To Improve Joint FunctionApplication PCTUS2023061392Pending
- Transmembrane Receptor Gene EditingApplication PCTUS2023060939Pending
- Gene Editing For Surgery Related Fibrosis TreatmentApplication 63480642Pending
- Transmembrane Receptor Gene EditingApplication 63390222Pending
- Gene Editing To Improve Joint FunctionApplication PCTUS2022037490Pending
- Lipid Nanoparticles For Gene Editing SystemsApplication 63342471Pending
- Gene Editing For Intervertebral, Intra- And Peridiscal Therapy And Associated Spinal DisordersApplication 63334476Pending
- Lipid Nano Particles For Gene Editing SystemsApplication 63362858Pending
- Gene Editing To Improve Joint FunctionApplication 63326571Pending
- INTERLEUKIN-1 Receptor Gene Editing To Improve Joint FunctionApplication 63303479Pending
- Gene Editing For Surgery Related Fibrosis TreatmentApplication 63303472Pending
- Gene Editing To Improve Joint FunctionApplication 63303290Pending
- Gene Editing For Musculo-skeletal Diseases TreatmentApplication 63303388Pending
Related companies, and why
- YAP Therapeutics IncSimilar federal contract value in Biotech · null in contracts
- La Jolla Labs IncSimilar federal contract value in Biotech · null in contracts
- Cairn Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- ProJenX, Inc.Similar federal contract value in Biotech · null in contracts
- Cyprotex PLCSimilar federal contract value in Biotech · null in contracts
- AV Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .